Mustang Bio, a clinical-stage biopharmaceutical company focused on developing innovative gene therapies for cancer, recently announced the publication of promising data from a Phase 1 clinical trial evaluating their investigational therapy, MB-101 IL13R2-targeted CAR T-cells, in patients with high-grade glioma. The findings were published in the prestigious scientific journal Nature Medicine, highlighting the potential of this therapy in treating this aggressive form of brain cancer.
Glioma is a type of tumor that arises from glial cells in the brain or spinal cord. High-grade glioma, in particular, is an aggressive and difficult-to-treat type of cancer with limited treatment options. Therefore, the results from this Phase 1 trial are highly significant, offering hope to patients battling this deadly disease.
The Phase 1 trial evaluated the safety and efficacy of MB-101 CAR T-cells in a cohort of patients with high-grade glioma. The treatment involves genetically modifying a patient’s own immune cells to express a chimeric antigen receptor (CAR) that specifically targets the IL13R2 protein on glioma cells. By doing so, the modified T-cells can effectively seek out and destroy cancer cells, while sparing healthy cells.
The study reported that MB-101 CAR T-cells were well-tolerated by the patients, indicating a favorable safety profile for this novel therapy. Furthermore, the results showed that 50% of the patients achieved stable disease or better, with two patients experiencing partial responses and two patients achieving complete responses. Impressively, the complete responses had durable durations of 7.5 and 66+ months, respectively.
Dr. Manuel Litchman, President and CEO of Mustang Bio, expressed enthusiasm regarding these findings, stating, The data published in Nature Medicine validate our approach and highlight the potential of MB-101 as a viable treatment option for patients with high-grade glioma. He further emphasized the importance of continuing the development of this therapy to further evaluate its efficacy and potential benefit for patients.
The positive results observed in this Phase 1 trial pave the way for further investigation, with Mustang Bio planning to initiate a Phase 2 study to evaluate the efficacy of MB-101 in a larger patient population. The focus of this trial will be to assess the therapy’s ability to induce a sustained response and potentially improve overall survival for patients with high-grade glioma.
The potential of MB-101 CAR T-cells in the treatment of high-grade glioma has garnered significant attention from the scientific community and the media. The groundbreaking data published in Nature Medicine supports the growing belief that CAR T-cell therapy represents a promising approach to combat this deadly form of brain cancer.
In conclusion, Mustang Bio’s Phase 1 trial evaluating the IL13R2-targeted CAR T-cell therapy, MB-101, has demonstrated encouraging results in patients with high-grade glioma. This innovative therapy has shown favorable safety profiles, with several patients achieving stable disease or better, including two remarkable complete responses lasting 7.5 and 66+ months, respectively. The publication of these results in Nature Medicine marks an important milestone in the advancement of CAR T-cell therapy for high-grade glioma, providing hope for patients and propelling further research in this field.
Now, for the
Comments